JNJ

227.84

+1.49%↑

ISRG

522.43

-0.51%↓

ABT

105.93

-2.09%↓

MDT

100.66

-0.05%↓

A

133.89

-1.33%↓

JNJ

227.84

+1.49%↑

ISRG

522.43

-0.51%↓

ABT

105.93

-2.09%↓

MDT

100.66

-0.05%↓

A

133.89

-1.33%↓

JNJ

227.84

+1.49%↑

ISRG

522.43

-0.51%↓

ABT

105.93

-2.09%↓

MDT

100.66

-0.05%↓

A

133.89

-1.33%↓

JNJ

227.84

+1.49%↑

ISRG

522.43

-0.51%↓

ABT

105.93

-2.09%↓

MDT

100.66

-0.05%↓

A

133.89

-1.33%↓

JNJ

227.84

+1.49%↑

ISRG

522.43

-0.51%↓

ABT

105.93

-2.09%↓

MDT

100.66

-0.05%↓

A

133.89

-1.33%↓

Search

Ascendis Pharma A-S ADR

Cerrado

SectorSalud

221.98 -6.48

Resumen

Variación precio

24h

Actual

Mínimo

221.36

Máximo

237.84

Métricas clave

By Trading Economics

Ingresos

-22M

-61M

Ventas

56M

214M

Margen de beneficio

-28.549

Empleados

1,017

EBITDA

-56M

-53M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+18.09% upside

Dividendos

By Dow Jones

Próximas Ganancias

11 feb 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

2.4B

14B

Apertura anterior

228.46

Cierre anterior

221.98

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Ascendis Pharma A-S ADR Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

28 ene 2026, 23:51 UTC

Ganancias

Correction to Samsung Fourth-Quarter Net Profit Article

28 ene 2026, 23:49 UTC

Acciones populares

Stocks to Watch: Meta, IBM, Las Vegas Sands, Whirlpool

28 ene 2026, 23:19 UTC

Ganancias

Samsung's Fourth-Quarter Net Profit Beats Consensus

28 ene 2026, 22:43 UTC

Ganancias

Waste Management Logs Higher 4Q Profit as Revenue Rises

29 ene 2026, 00:00 UTC

Adquisiciones, fusiones, absorciones

Diller's Overture Came Before Warner Unveiled Split Plans, Source Says -- WSJ

29 ene 2026, 00:00 UTC

Adquisiciones, fusiones, absorciones

Warner Says CNN Wasn't and Isn't for Sale -- WSJ

29 ene 2026, 00:00 UTC

Adquisiciones, fusiones, absorciones

Barry Diller Told Warner Bros. Discovery He Is Interested in Buying CNN -- WSJ

29 ene 2026, 00:00 UTC

Adquisiciones, fusiones, absorciones

Barry Diller Approached Warner Bros. Discovery Last Year About Buying CNN, Sources Say -- WSJ

28 ene 2026, 23:49 UTC

Charlas de Mercado

Nikkei May Rise as Weaker Yen Supports Earnings Hopes -- Market Talk

28 ene 2026, 23:30 UTC

Charlas de Mercado

Tesla to Use Car Factory for Robot Aims -- Market Talk

28 ene 2026, 23:28 UTC

Ganancias

Microsoft's Earnings Surge, Elevated by Cloud Business -- 3rd Update

28 ene 2026, 23:26 UTC

Ganancias

Meta Reports Record Sales, Massive Spending Hike on AI Buildout -- 2nd Update

28 ene 2026, 23:21 UTC

Ganancias

Microsoft Stock Falls Despite Earnings Beat. Cloud Growth Slowed Slightly. -- Barrons.com

28 ene 2026, 23:18 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Tesla to Invest $2 Billion in Elon Musk's xAI -- Update

28 ene 2026, 22:58 UTC

Ganancias

Tesla to Invest $2 Billion in Elon Musk's xAI -- Update

28 ene 2026, 22:48 UTC

Charlas de Mercado

Woodside Energy Has Form With Conservative Production Guidance -- Market Talk

28 ene 2026, 22:45 UTC

Ganancias

Samsung Electronics 2025 Net KRW45.207T Vs. Net KRW34.451T >005930.SE

28 ene 2026, 22:44 UTC

Ganancias

Samsung Electronics 2025 Oper Pft KRW43.601T Vs. Pft KRW32.726T >005930.SE

28 ene 2026, 22:43 UTC

Ganancias

Samsung Electronics 2025 Rev KRW333.606T Vs. KRW300.871T >005930.SE

28 ene 2026, 22:41 UTC

Ganancias
Acciones populares

Earnings in Focus Wednesday: Microsoft, Tesla, Meta, Starbucks -- WSJ

28 ene 2026, 22:41 UTC

Charlas de Mercado

Rising AUD Typically Sees Australian Stocks Outperform -- Market Talk

28 ene 2026, 22:41 UTC

Ganancias

Meta Stock Rises on Strong Earnings. Expenses Are Mounting. -- Barrons.com

28 ene 2026, 22:40 UTC

Ganancias

Samsung Electronics 4Q Net Profit Beat FactSet-Compiled Consensus

28 ene 2026, 22:39 UTC

Ganancias

Samsung Electronics 4Q Net KRW19.642T Vs. Net KRW7.754T >005930.SE

28 ene 2026, 22:38 UTC

Ganancias

Samsung Electronics 4Q Oper Pft KRW20.074T Vs. Pft KRW6.493T >005930.SE

28 ene 2026, 22:37 UTC

Ganancias

Samsung Electronics 4Q Rev KRW93.837T Vs. KRW75.788T >005930.SE

28 ene 2026, 22:35 UTC

Ganancias

Microsoft Stock Falls Despite Earnings Beat. Cloud Growth Slowed Slightly. -- Barrons.com

28 ene 2026, 22:26 UTC

Charlas de Mercado
Ganancias

Meta's Rising CapEx is Fueled by High Pay for AI Workers -- Market Talk

28 ene 2026, 22:20 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

28 ene 2026, 22:20 UTC

Charlas de Mercado

Woodside Energy's Oil Assets Blamed for Guidance Miss -- Market Talk

Comparación entre iguales

Cambio de precio

Ascendis Pharma A-S ADR Esperado

Precio Objetivo

By TipRanks

18.09% repunte

Estimación a 12 meses

Media 275.92 USD  18.09%

Máximo 342 USD

Mínimo 240 USD

De acuerdo con 13 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Ascendis Pharma A-S ADR Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

13 ratings

13

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

157.66 / 167.29Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Bullish Evidence

Largo Plazo

Strong Bullish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Ascendis Pharma A-S ADR

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
help-icon Live chat